Thought leaders discuss patient scenarios and different factors to consider when deciding how to select and utilize bridging therapy in the management of patients with LBCL.
Retrospective Analysis Shows Efficacy and Safety of CAR T-Cell Therapy in MCL With SCNS
Revisit the OncLive On Air Episodes From February 2024
Ongoing Research Aims to Expand Treatment Options, Address Unmet Needs in GVHD
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward
Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC